• Quest Pharmatech Inc., of Edmonton, Alberta, said it continued an exclusive license agreement with Stanford University to develop and market anti-MUC1 IgE technology for the treatment of cancer.

Abstracts of the data that are to be presented at the American Society of Hematology’s annual meeting next month were released Thursday. And the biggest market response to trial data involved Geron Corp’s myelofibrosis drug Imetelstat.

• Supernus Pharmaceuticals Inc., of Rockville, Md., said that in a single-blind, randomized-sequence, crossover study in healthy adults, Trokendi (SPN-538), produced more consistent plasma concentrations of topiramate compared to topiramate.

What could be the first chapter in a sequel to the Jumpstart Our Business Startups (JOBS) Act was unveiled Wednesday with the hope that it soon will become a congressional best-seller that will stimulate investment in groundbreaking R&D.

The FDA’s partial clinical hold on CUDC-427 because of a cancer patient’s death from liver failure overshadowed third-quarter earnings for Curis Inc., which is analyzing possible causes.

Vivus Inc. reported disappointing sales for its obesity drug Qsymia (phentermine/topiramate), driving its stock price down more than 12 percent. The drug brought in $6.4 million in net revenue in the third quarter of 2013, missing consensus estimates of $12 million by a wide margin. The company’s net loss for the quarter was $48 million, or 48 cents per share, compared to a net loss of $40.4 million, or 40 cents per share, in the third quarter of 2012.

VIENNA – It may be pushing the concept of pathetic fallacy a little hard to suggest that the early morning sunshine greeting delegates filing into the Wien Exhibition & Congress Center for the final day of BIO-Europe represented a new dawn for European biotechnology.

Scientists have identified an enzyme whose function is important for the survival of tuberculosis bacteria regardless of whether they are currently dividing or not.